UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in adults with moderate-to-severe hidradenitis suppurativa (HS).

By Tusker No matter how effective a benefit should be with your workforce, without a great communication strategy they can go unused. In fact, research has revealed that up to 42% of employees either ...